Hospital
Pend Oreille County Public Hospital District No 1
Pend Oreille County Public Hospital District No 1 was paid $11.61M by Medicaid between Jan 2018 and Dec 2024, across 136 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoPEND OREILLE COUNTY PUBLIC HOSPITAL DISTRICT NO 1
NEWPORT, WA 99156
NEWPORT, WA 99156
33aNPI1780778423assigned 10/03/2006
33bProvider typeCritical Access Hospital
28Total paid$11.61M
24GClaims156,370
24DCodes billed136
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Washington
Rank by total paid#11 of 30
Median peer was paid$9.10M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,708 | $1.31M | |
| 2019 | 28,229 | $1.73M | |
| 2020 | 21,361 | $1.41M | |
| 2021 | 20,480 | $1.45M | |
| 2022 | 20,128 | $1.85M | |
| 2023 | 21,551 | $2.06M | |
| 2024incomplete | 19,913 | $1.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 9,388 | 7,830 | $2.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 6,708 | 5,106 | $1.94M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.5% | 2,633 | 1,981 | $986K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.2% | 11,908 | 3,810 | $833K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 1,043 | 994 | $680K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 3,593 | 3,212 | $444K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 2,741 | 2,498 | $435K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.6% | 6,878 | 2,488 | $303K |
| 80053 | Comprehensive metabolic panel | 2.5% | 10,386 | 9,261 | $291K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 1,589 | 1,134 | $257K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 10,858 | 9,526 | $215K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.6% | 464 | 454 | $183K |
124 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 3,095 | $155K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 2,474 | $135K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 2,358 | $135K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 924 | $128K |
| 80061 | Lipid panel | 1.1% | 2,480 | $127K |
| 97162 | 1.1% | 819 | $123K | |
| 97014 | <1% | 4,399 | $111K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,255 | $109K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,550 | $109K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,061 | $104K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,640 | $102K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 444 | $81K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,502 | $74K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,214 | $73K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 571 | $64K |
| 36592 | <1% | 1,187 | $61K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,389 | $56K |
| 80050 | General health panel | <1% | 392 | $53K |
| 80306 | <1% | 1,202 | $53K | |
| 84484 | <1% | 1,852 | $50K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,071 | $50K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,875 | $48K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 596 | $45K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 978 | $45K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,322 | $40K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,028 | $39K |
| 83690 | <1% | 2,051 | $38K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 443 | $37K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 442 | $37K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,197 | $35K |
| 81001 | <1% | 3,804 | $35K | |
| 83880 | <1% | 501 | $29K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 815 | $28K |
| 73564 | <1% | 344 | $27K | |
| 85027 | <1% | 1,379 | $25K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 190 | $25K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 215 | $25K |
| 86140 | <1% | 1,764 | $24K | |
| 87634 | <1% | 175 | $23K | |
| J2704 | Injection, propofol, 10 mg | <1% | 587 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 769 | $19K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,688 | $19K |
| 87641 | <1% | 250 | $19K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 287 | $17K |
| 73030 | <1% | 313 | $16K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 102 | $15K |
| 87070 | <1% | 494 | $14K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 41 | $14K |
| 86703 | <1% | 282 | $13K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 80 | $13K |
| 73610 | <1% | 228 | $13K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 112 | $13K |
| 81025 | <1% | 458 | $12K | |
| 97010 | <1% | 2,156 | $11K | |
| 73630 | <1% | 204 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 127 | $11K |
| 97026 | <1% | 1,165 | $10K | |
| 86803 | <1% | 176 | $9K | |
| 97035 | <1% | 470 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 315 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 217 | $8K |
| 82607 | <1% | 119 | $8K | |
| 73130 | <1% | 119 | $8K | |
| 85610 | <1% | 827 | $7K | |
| 83605 | <1% | 326 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 120 | $7K |
| 85651 | <1% | 575 | $7K | |
| 73110 | <1% | 97 | $6K | |
| 87077 | <1% | 292 | $6K | |
| 84703 | <1% | 256 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 57 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 73 | $5K |
| 97161 | <1% | 30 | $5K | |
| 84153 | <1% | 64 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 26 | $5K |
| 87186 | <1% | 205 | $5K | |
| 81003 | <1% | 773 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 91 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 18 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 197 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 166 | $4K |
| 36416 | <1% | 490 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 82 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 66 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 127 | $3K |
| 90715 | <1% | 41 | $3K | |
| 82947 | <1% | 263 | $3K | |
| 85379 | <1% | 107 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 31 | $3K |
| 82570 | <1% | 169 | $3K | |
| 87210 | <1% | 173 | $2K | |
| 76801 | <1% | 12 | $2K | |
| 83874 | <1% | 78 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 37 | $2K |
| 82553 | <1% | 77 | $2K | |
| J3490 | Unclassified drugs | <1% | 19 | $2K |
| 87220 | <1% | 146 | $2K | |
| 82043 | <1% | 111 | $2K | |
| 82550 | <1% | 124 | $2K | |
| 73502 | <1% | 29 | $2K | |
| 83735 | <1% | 74 | $1K | |
| 84439 | <1% | 51 | $1K | |
| 72100 | <1% | 24 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 135 | $989.81 |
| 80076 | <1% | 32 | $927.55 | |
| 87205 | <1% | 62 | $697.59 | |
| 84466 | <1% | 14 | $690.98 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $671.71 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 535 | $664.80 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 31 | $554.97 |
| 74018 | <1% | 13 | $398.05 | |
| 83540 | <1% | 14 | $389.53 | |
| 84145 | <1% | 12 | $369.56 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 13 | $279.52 |
| 86850 | <1% | 15 | $258.73 | |
| 86900 | <1% | 29 | $220.34 | |
| 82962 | <1% | 38 | $188.75 | |
| 86901 | <1% | 15 | $101.01 | |
| 85652 | <1% | 13 | $82.62 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12 | $20.09 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 172 | $3.71 |
| 96376 | <1% | 17 | $0.10 | |
| A9270 | Non-covered item or service | 0% | 703 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMANUS, KIM (CEO)
| Provider | Location | Paid |
|---|---|---|
| Pend Oreille County Public Hospital District No 1 | Newport, WA | $10.67M |
| Pend Oreille County Public Hospital District No 1 | Newport, WA | $747K |
| Pend Oreille County Public Hospital District No 1 | Newport, WA | $453.67 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.